KIFC1 depends on TRIM37-mediated ubiquitination of PLK4 to promote centrosome amplification in endometrial cancer

• Published in: Cell death discovery Vol. 10; no. 1; p. 419
• Main Authors: Zhou, Kening, He, Yingying, Lin, Xi, Zhou, Huihao, Xu, Xiaomin, Xu, Jingui
• Format: Journal Article
• Language: English
• Published: United States Springer Nature B.V 30.09.2024; Nature Publishing Group UK
• Subjects: Cell cycle; Centrosomes; Endometrial cancer; Endometrium; Genomic instability; Kinesin; Metastases; Reproductive health; Therapeutic targets; Ubiquitin-protein ligase; Ubiquitination; Uterine cancer
• ISSN: 2058-7716; 2058-7716
• DOI: 10.1038/s41420-024-02190-1

Endometrial cancer (EC), as one of the most common cancers, severely threatens female reproductive health. Our previous study has shown that Kinesin family member C1 (KIFC1) played crucial roles in the progression of EC. In addition, abnormal centrosome amplification, which was reported to be partially regulated by KIFC1, usually occurred in different cancers. However, whether KIFC1 promoted EC through centrosome amplification and the potential mechanism remain to be revealed. The present study demonstrated that overexpressed KIFC1, which exhibited a worse prognosis, had a positive correlation with an increased number of centrosomes in human EC samples. In addition, KIFC1 overexpression in EC cells prompted centrosome amplification, chromosomal instability, and cell cycle progression. Moreover, we demonstrated that KIFC1 inhibited E3 ubiquitin-protein ligase TRIM37 to maintain the stability of PLK4 by reducing its ubiquitination degradation, and finally promoting centrosome amplification and EC progression in vitro. Finally, the contributing role of KIFC1 and the inhibitory effect of TRIM37 on EC development and metastasis was verified in a nude mouse xenograft model. Our study elucidated that KIFC1 depends on TRIM37-mediated reduced ubiquitination degradation of PLK4 to promote centrosome amplification and EC progression, thus providing a potential prognostic marker and promising therapeutic target for EC in the future.